Rovi stock: pharmaceutical laboratory at EUR 57.18 pre-market
Published on 10/20/2026 at 07:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCompany profile and reporting date
- Rovi operates as a pharmaceutical laboratory in the health field.
- The investor calendar lists first nine months 2026 financial results for November 5, 2026.
- Rovi stock trades pre-market at EUR 57.18 at 7:33 a.m. CEST at Lang & Schwarz on October 20, 2026.
Laboratorios Farmacéuticos ROVI, S.A. describes itself as a pharmaceutical laboratory operating in the health field on its investor-relations site. Rovi stock trades pre-market at EUR 57.18 at 7:33 a.m. CEST at Lang & Schwarz on October 20, 2026.
Ahead of the Xetra open
The pre-market indication is recorded before the Xetra session begins at 9:00 a.m. CEST. The company’s investor calendar lists first nine months 2026 financial results for November 5, 2026, under its next events. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Rovi stock.
Business and upcoming results
Rovi operates as a pharmaceutical laboratory in the health field, and its website provides information on the company’s activities, products and health-related work. The investor calendar identifies November 5, 2026, as the date for the first nine months 2026 financial results. This is the next company event listed on the Rovi investor-relations page.
Market context: Market report IBEX 35.
